ArticleTranslational lung cancer research2025
Prognostic impacts of skip metastasis in N2a and N2b subgroups of non-small cell lung cancer: insights from a large cohort.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Skip N2 Metastasis in Resected Lung Cancer: Prognostic Subclassification by Lymphatic Drainage and Histology.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Development and validation of a multi-center prognostic model for predicting survival in non-small cell lung cancer using pulmonary and hematological data.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of skip metastasis remains controversial in the context of the recently revised N2a (single-station) and N2b (multi-station) of non-small cell lung cancer (NSCLC). This study aims to investigate the survival impact of skip metastasis in these subgroups. Methods: We retrospectively analyzed 1,873 NSCLC patients who underwent surgery with systematic lymph node dissection at a single institution. Patients were categorized into pN1, skip pN2a, non-skip pN2a, skip pN2b, and non-skip pN2b groups. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier analysis and Cox proportional hazards regression, with propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) applied to minimize confounding. Results: Skip metastasis was identified in 34.1% of pN2 cases, with a higher incidence in pN2a (41.3%) than in pN2b (24.3%). Skip pN2a showed significantly better 5-year OS and DFS rates compared to non-skip pN2a (72% Conclusions: Skip metastasis confers a survival advantage in both pN2a and pN2b NSCLC subgroups with comparable survival between skip pN2a and pN1, as well as between non-skip pN2a and skip pN2b.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.